In a strategic move emphasizing its heritage, Regal Holdings has rebranded its core manufacturing division as the historic West Bend Co., underscoring a commitment to U.S. production and Wisconsin's industrial legacy.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
Japan's manufacturing activity expanded at its fastest pace since mid-2022 in January, a key private survey shows, driven by robust domestic and international orders. While the sector's revival is clear, rising input costs and inflation concerns temper the optimism.
Simpson Manufacturing Co. (NYSE: SSD) has inaugurated a new production facility in Gallatin, Tennessee, marking a strategic step in its operational expansion. The move comes as investors assess the company's valuation following a period of strong stock performance.
Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) have surged over 50% in the last three months, reigniting debate over its fair value and the risks tied to its lead drug OJEMDA and a pivotal upcoming data readout.
Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.
SLB has won significant five-year contracts from Petroleum Development Oman for the giant Block-6 field. The deals mandate local wellhead manufacturing and deploy advanced recovery technologies, anchoring SLB's long-term service role and supporting Omani job creation.
Deere & Company is doubling down on American manufacturing with a new excavator plant and parts center, part of a broader $20 billion commitment. While the move strengthens its long-term industrial narrative, near-term challenges from leadership changes to cyclical market pressures remain in focus.
Amneal Pharmaceuticals' shares have surged over 64% in the past year, prompting investors to question if the rally still has room to run. A closer look at valuation metrics suggests the generic drugmaker may still be trading at a significant discount to its intrinsic value.
Homebuilding giant PulteGroup announces the sale of its off-site manufacturing division, pivoting to a partnership model to streamline operations and concentrate on its core business as it navigates a persistent valuation gap with peers.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility dedicated to next-generation weight-loss drugs, signaling a long-term strategic commitment to the obesity market amid intense competition.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
Pharmaceutical leader Eli Lilly will build a new manufacturing facility in Lehigh County, marking the largest life sciences investment in Pennsylvania history and bolstering U.S. production of next-generation weight-loss drugs.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
General Motors is cutting over 700 positions at its Oshawa, Ontario plant, redirecting investment and workforce development to its U.S. facilities. The move underscores a strategic realignment of North American operations amid evolving trade dynamics and a focus on core truck and SUV programs.
China's factory activity unexpectedly contracted in January, official data shows, reversing a brief December expansion and underscoring persistent domestic demand challenges despite robust exports.
While Tesla's Fremont facility will produce the upcoming Optimus 3, CEO Elon Musk reveals that the subsequent, higher-volume Optimus 4 generation will be manufactured at Gigafactory Texas, marking a strategic pivot in the company's automation roadmap.
Chinese electric vehicle giant BYD is deepening its international footprint, announcing new assembly plans in India, a strategic pivot in Mexico, and a battery plant partnership in Vietnam, as it seeks to insulate itself from trade barriers and tap into regional growth.
The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.
